sirna
exert
biolog
effect
guid
degrad
cognat
mrna
sequenc
therebi
shut
correspond
protein
product
gene
silenc
rna
interfer
rnai
due
properti
sirna
emerg
promis
therapeut
agent
treatment
inherit
acquir
diseas
well
research
tool
elucid
gene
function
health
diseas
lethal
preval
lung
diseas
attract
particular
attent
target
sirnamedi
cure
addit
lung
access
therapeut
agent
via
multipl
rout
eg
nose
mouth
thu
obviat
need
target
make
appeal
target
rnaibas
therapeut
strategi
clinic
success
sirnamedi
intervent
critic
depend
upon
safeti
efficaci
deliveri
method
agent
deliveri
sirna
relev
lung
diseas
attempt
multipl
rout
use
variou
carrier
anim
model
review
focus
recent
progress
nonvir
deliveri
sirna
treatment
lung
diseas
particularli
infecti
diseas
rapid
progress
put
sirnabas
therapeut
fast
track
clinic
rna
interfer
rnai
posttranscript
gene
silenc
phenomenon
wherein
doublestrand
rna
dsrna
trigger
degrad
homolog
messeng
rna
mrna
believ
play
critic
role
defens
viral
attack
specif
initi
step
exogen
eg
viral
dsrna
digest
enzym
dicer
member
rnase
iii
famili
dsrnaspecif
ribonucleas
short
interf
rna
sirna
bp
length
effector
step
antisens
strand
sirna
incorpor
rnainduc
silenc
complex
risc
risc
target
mrna
complementari
sirna
within
complex
cleav
target
mrna
thu
lead
inhibit
mrna
translat
mammalian
cell
rnai
trigger
synthet
rna
duplex
nt
long
guid
degrad
cognat
mrna
sequenc
henc
halt
correspond
protein
product
sirna
may
obtain
chemic
synthesi
express
dnavector
latter
dna
insert
bp
encod
short
hairpin
rna
shrna
target
gene
interest
clone
express
vector
insertcontain
vector
transfect
cell
express
shrna
rapidli
process
cellular
machineri
nt
doublestrand
rna
dsrna
rnai
confer
transient
interfer
gene
express
sequencespecif
manner
repres
new
class
nucleic
acidbas
molecul
like
signific
medic
util
fact
rnai
view
one
import
recent
discoveri
biolog
due
gener
phenomenon
sirna
sequenc
could
design
virtual
target
mrna
methodolog
could
exploit
therapeut
use
research
tool
mani
way
exampl
protein
interest
could
mutat
human
protein
case
huntington
diseas
hd
autosom
domin
inherit
neurodegen
disord
current
without
effect
treatment
caus
expand
polyglutamin
poli
q
tract
correspond
protein
huntingtin
suppress
huntingtin
express
neuron
brain
expect
delay
onset
mitig
sever
hd
instanc
rnai
protein
interest
could
foreign
case
influenza
infect
sar
target
protein
encod
viral
genom
addit
sirna
could
use
research
tool
elucid
gene
function
compar
expens
timeconsum
convent
gene
knockdown
experi
sirnabas
gene
silenc
cheaper
faster
use
establish
biolog
function
phenotyp
effect
mani
gene
involv
health
diseas
size
chemic
degrad
physiolog
relev
condit
deliveri
sirna
usual
requir
vector
carrier
transfect
mammalian
cell
mani
nonvir
vector
previous
test
dna
deliveri
adapt
sirna
sinc
barrier
deliveri
similar
due
locat
physiolog
function
lung
suscept
mani
diseas
exampl
expos
mani
environment
pollut
includ
pollen
smoke
ozon
volatil
organ
compound
lead
diseas
asthma
cancer
furthermor
mani
lethal
infecti
diseas
influenza
sar
airborn
use
lung
target
site
main
entranc
bodi
given
lethal
preval
lung
diseas
attract
particular
attent
target
sirnamedi
cure
addit
sinc
lung
access
therapeut
agent
via
multipl
rout
nose
mouth
thu
obviat
need
target
conveni
model
vivo
valid
sirnamedi
therapeut
gene
silenc
neg
charg
chemic
degrad
sirna
physiolog
relev
condit
make
deliveri
major
challeng
owe
chemic
similar
dna
rna
barrier
deliveri
like
similar
dna
extens
investig
context
gene
therapi
may
group
intracellular
extracellular
barrier
type
nucleic
acid
must
cross
cell
membran
success
escap
lysosom
degrad
neg
charg
size
sirna
plasmid
dna
typic
molecular
weight
kda
kda
respect
impli
bind
cell
surfac
cross
cell
membran
passiv
diffus
howev
plasmid
dna
need
enter
nucleu
initi
transcript
encod
gene
sirna
function
cytosol
therefor
achiev
therapeut
effect
deliveri
nucleic
acid
nondivid
cell
may
easili
achiev
sirna
dna
extracellular
barrier
sirna
deliveri
depend
upon
rout
administr
eg
intraven
iv
intranas
intratrach
subcutan
intratumor
intramuscular
oral
turn
depend
upon
target
diseas
case
iv
deliveri
exampl
first
major
extracellular
obstacl
degrad
serum
nucleas
may
overcom
complex
suitabl
agent
complex
agent
also
facilit
cellular
uptak
endosom
escap
sinc
charg
complementar
aid
complex
format
bind
neg
charg
sirna
carrier
typic
posit
charg
nonvir
sirna
transfect
carrier
categor
lipidand
polycationbas
one
lipofectamin
cardiolipin
analogu
success
use
deliveri
sirna
case
lipidmedi
sirna
transfect
shown
least
thousand
fold
effici
nake
sirna
sirnadna
transfect
mediat
cation
lipid
neg
charg
nucleic
acid
posit
charg
lipid
spontan
form
nanoparticl
known
lipoplex
nm
diamet
absenc
serum
particl
posit
surfac
charg
henc
favor
interact
cell
make
suitabl
effici
sirna
deliveri
although
interact
serum
compon
may
major
factor
influenc
perform
use
system
bioavail
celltypespecif
deliveri
vivo
pharmacokinet
depend
rout
administr
import
paramet
decid
vivo
gene
silenc
efficaci
unfortun
inform
biodistribut
nake
formul
sirna
chemic
modifi
analogu
rather
scarc
lipidmedi
deliveri
sirna
apolipoprotein
b
apob
use
target
apob
mrna
liver
wherea
administr
apobspecif
sirna
without
formul
chemic
conjug
dose
higher
mgkg
previous
shown
vivo
silenc
activ
silenc
liver
apob
mrna
protein
achiev
singl
mgkg
dose
lipidformul
nonhuman
primat
lipid
formul
case
contain
lipid
ethylen
glycol
carbamoyl
pegcdma
dlindma
dspc
cholesterol
molar
ratio
major
fraction
sirna
deliv
intraven
use
vector
accumul
liver
follow
spleen
small
intestin
lower
accumul
similar
lipidbas
transfect
carrier
posit
charg
polyc
allow
effici
interact
sirna
form
polyplex
bind
onto
cell
plasma
membran
endocytos
unlik
lipoplex
reli
fusogen
properti
liposom
mediat
endosom
escap
polymer
carrier
polyethylenimin
pei
use
socal
proton
spong
effect
enhanc
endosom
releas
endocytos
polyplex
accord
mechan
unproton
amin
differ
pk
valu
confer
buffer
effect
wide
rang
ph
buffer
may
protect
sirna
degrad
endosom
compart
matur
earli
endosom
late
endosom
subsequ
fusion
lysosom
buffer
properti
also
allow
polyc
polyethylenimin
pei
escap
endosom
lower
ph
buffer
pei
caus
influx
chlorid
ion
water
endosom
eventu
burst
due
increas
osmot
pressur
thu
facilit
intracellular
releas
peisirna
polyplex
high
cation
densiti
pei
potenti
posit
charg
per
da
monom
molecular
weight
also
contribut
format
highli
condens
particl
interact
nucleic
acid
howev
also
result
signific
cytotox
particularli
larg
pei
nucleic
acid
specif
case
sirna
deliveri
lung
extracellular
barrier
depend
upon
rout
administr
introduct
complex
lung
could
achiev
principl
system
rout
first
two
particularli
appeal
sinc
offer
uniqu
opportun
specif
deliveri
sirna
airway
alveolar
epithelium
larg
bodi
literatur
experi
gene
deliveri
lung
support
feasibl
approach
howev
airwaydirect
gene
deliveri
simpl
lung
evolv
physic
immunolog
barrier
hinder
effect
transduct
epitheli
cell
besid
physic
phenomena
cilia
beat
mucociliari
clearanc
possibl
interact
complex
airway
surfac
liquid
asl
cover
airway
epitheli
cell
pose
anoth
major
barrier
major
constitu
asl
phospholipid
protein
mucin
highmolecularweight
glycosyl
protein
could
affect
nucleic
acid
transfer
effici
first
neg
charg
asl
constitu
could
directli
bind
posit
charg
complex
alter
size
switch
overal
charg
neg
henc
affect
diffus
target
cell
cellular
uptak
addit
bind
neg
charg
asl
compon
might
displac
nucleic
acid
complex
consequ
lower
deliveri
effici
fact
lung
surfact
shown
imped
cation
liposomemedi
dna
transfect
exampl
alveofact
natur
surfact
extract
bovin
lung
lavag
inhibit
gene
transfer
mediat
cation
liposom
vitro
interestingli
polycationmedi
gene
transfer
affect
neither
vitro
vivo
surfact
contrast
bronchoalveolar
lavag
fluid
balf
collect
bronchoscopi
inhibit
liposomeand
polycationmedi
gene
transfer
major
inhibitori
effect
case
shown
caus
adsorpt
balf
protein
complex
result
alter
surfac
charg
due
releas
dna
complex
addit
patient
diseas
cystic
fibrosi
character
lung
patholog
thick
mucu
product
direct
deliveri
lung
via
intranas
intratrach
rout
like
challeng
recent
studi
shown
cation
lipidmedi
sirna
transfer
airway
epitheli
cell
vivo
ineffici
follow
vivo
lung
transfect
use
genzym
http
wwwgenzymecom
lipid
mice
sirna
visibl
alveolar
macrophag
sirna
target
reduc
mrna
level
airway
epithelium
mice
howev
insuffici
reduc
protein
express
consid
forego
difficulti
system
administr
may
perceiv
altern
intranas
intratrach
administr
complex
inform
biodistribut
complex
sirna
cation
liposom
polyc
system
administr
rather
scarc
owe
similar
sirna
dna
consid
case
complex
dna
would
instruct
biodistribut
latter
complex
process
depend
colloid
properti
well
interact
blood
compon
exampl
experi
involv
gene
deliveri
liver
dnapolyc
complex
nm
diamet
unlik
larger
complex
transport
parenchym
cell
furthermor
scaveng
cell
usual
absorb
complex
bear
strong
anion
charg
result
elimin
genet
materi
bodi
strong
posit
charg
complex
also
deleteri
exampl
follow
intraven
administr
mice
dose
plasmid
dna
deliv
complex
cation
liposom
accumul
liver
time
level
transgen
express
per
microgram
dna
taken
tissu
lower
liver
lung
appar
decreas
transgen
express
liver
due
rapid
degrad
dna
follow
phagocytosi
lipoplex
kupffer
cell
distribut
transgen
express
follow
administr
dnapolyc
complex
similar
describ
express
primarili
observ
lung
much
lesser
extent
major
organ
spleen
liver
heart
interestingli
transgen
express
significantli
alter
plasmid
dna
formul
polyc
graft
hydrophil
polym
pluron
case
express
report
gene
evenli
distribut
among
aforement
major
organ
similar
case
dna
iv
inject
sirna
pegcontain
liposom
also
report
result
preferenti
deliveri
sirna
liver
impli
surfac
properti
polyplex
import
factor
dictat
vivo
distribut
preferenti
gene
express
lung
upon
iv
deliveri
dna
complex
unmodifi
cation
liposom
polyc
rather
fortuit
context
lungaffect
diseas
may
exploit
sirna
deliveri
treatment
lung
diseas
noteworthi
intranas
deliveri
nake
sirna
shown
result
therapeut
gene
silenc
effici
nonvir
vector
plausibl
reason
success
method
degrad
sirna
nucleas
signific
airway
unlik
rout
iv
wherein
signific
gene
silenc
observ
nake
sirna
infecti
diseas
lung
target
nonvir
sirna
deliveri
influenza
viru
caus
one
preval
infect
human
typic
year
unit
state
popul
infect
viru
result
death
hospit
http
wwwcdcgovflu
influenza
pandem
caus
new
strain
viruson
human
immunityacquir
abil
readili
infect
peopl
base
global
popul
estim
billion
peopl
estim
mortal
rate
spanish
flu
pandem
next
pandem
might
kill
least
million
peopl
pandem
strain
prove
highli
virul
number
could
much
higher
current
vaccin
prevent
ill
healthi
individu
age
protect
rate
drop
suscept
infect
name
elderli
infant
individu
weaken
immun
system
furthermor
influenza
vaccin
need
formul
year
viral
antigen
ha
na
elicit
neutral
antibodi
chang
render
previou
year
vaccin
ineffect
new
subtyp
sinc
take
month
produc
vaccin
decis
must
made
advanc
viru
strain
includ
constrain
applic
vaccin
face
approach
epidem
addit
shortag
vaccin
flu
season
often
aris
due
technic
difficulti
vaccin
product
process
exampl
chiron
corpor
could
provid
none
influenza
vaccin
distribut
unit
state
flu
season
medicin
healthcar
product
regulatori
agenc
mhra
unit
kingdom
produc
suspend
chiron
licens
manufactur
vaccin
liverpool
facil
month
thu
prevent
releas
vaccin
influenza
season
action
prompt
vaccin
contamin
deadli
bacterium
cut
roughli
half
expect
suppli
trival
inactiv
vaccin
flu
shot
avail
unit
state
winter
mishap
underscor
need
altern
strategi
prevent
treatment
influenza
although
four
antivir
drug
approv
unit
state
treatment
andor
prophylaxi
influenza
use
limit
concern
side
effect
risk
emerg
drugresist
strain
influenza
viru
envelop
viru
orthomyxoviru
famili
influenza
virion
usual
roughli
spheric
nm
diamet
viral
genom
compos
eight
segment
singlestrand
rna
neg
polar
coat
rnabind
protein
nucleocapsid
protein
np
form
nucleocapsid
overli
nucleocapsid
layer
matrix
protein
turn
surround
viral
envelop
deriv
host
cell
membran
viru
classifi
influenza
b
c
type
base
differ
np
virus
belong
type
classifi
subtyp
accord
serotyp
ha
na
protein
influenza
type
b
c
infect
caus
mild
respiratori
ill
thought
caus
epidem
found
sirna
specif
conserv
region
influenza
viru
genom
potent
inhibitor
influenza
infect
vitro
vivo
design
sirna
effect
influenza
focus
region
viral
genom
conserv
among
differ
subtyp
strain
viru
human
swine
equin
duck
chicken
despit
antigen
drift
shift
total
sirna
specif
np
pa
ns
gene
design
ha
na
select
sirna
target
due
extens
variat
gene
among
differ
viru
isol
abil
synthet
sirna
inhibit
influenza
viru
product
cell
cultur
test
introduc
sirna
cell
viru
infect
electropor
assay
viru
titer
cultur
supernat
differ
time
infect
also
verifi
chicken
embryo
latter
case
sirna
introduc
complex
commerci
liposom
reagent
oligofectamin
follow
conclus
drawn
studi
influenza
viru
product
inhibit
sirna
specif
differ
viral
gene
especi
encod
np
pa
ii
inhibitori
effect
sirna
observ
cell
infect
viru
prior
introduct
sirna
iii
sirna
inhibit
influenza
viral
product
cultur
cell
also
inhibit
viral
product
chicken
embryo
iv
msirna
specif
inhibit
accumul
mmrna
sirna
specif
np
pa
abolish
accumul
correspond
mrna
also
vrna
crna
suggest
critic
role
np
pa
protein
viral
transcript
replic
target
mrna
degrad
result
global
inhibit
viral
rna
transcript
make
npand
paspecif
sirna
especi
potent
inhibitor
influenza
viral
infect
set
test
feasibl
influenza
inhibit
mice
peimedi
sirna
deliveri
model
first
test
abil
jetpei
proprietari
linear
pei
formul
polyplustransfect
illkrich
franc
deliv
luc
luciferas
gene
lung
mice
also
efficaci
jetpeiluc
sirna
complex
inhibit
express
luc
lung
consist
previou
find
jetpeidna
complex
inject
iv
retroorbit
vein
luc
activ
highest
lung
could
detect
least
day
heart
liver
spleen
kidney
luc
activ
time
lower
depend
upon
peidna
ratio
detect
shorter
period
inject
jetpeidna
complex
administ
luciferas
express
lung
lower
lucsirnajet
pei
complex
deliv
iv
result
suppress
express
luc
gene
deliv
complex
jetpei
gfpsirnajetpei
gfp
green
fluoresc
protein
complex
effect
express
luc
sinc
lucsirna
inhibit
luc
express
lung
cell
transfect
lucdna
result
indic
jetpei
deliv
sirna
effect
lung
cell
mice
henc
deliveri
appropri
sirnajetpei
complex
may
use
inhibit
influenza
infect
lung
reason
rel
higher
deliveri
complex
dna
sirna
pei
clear
may
lung
contain
first
capillari
bed
travers
ivinject
materi
ii
among
vascular
tissu
bodi
also
notic
rel
express
lung
compar
organ
higher
surfac
charg
complex
cation
posit
zeta
potenti
signific
reduct
viru
titer
observ
npor
pasirna
complex
jetpei
administ
iv
h
infect
mice
pfu
plaqu
form
unit
influenza
viru
influenza
apuerto
subtyp
reduct
viru
titer
observ
sirna
administ
pb
gfpsirna
use
complex
jetpei
complex
npand
pasirna
jetpei
inject
togeth
even
greater
reduct
viru
titer
observ
although
effect
may
seem
modest
lung
viru
titer
reduct
magnitud
usual
accompani
surviv
lethal
challeng
vaccin
develop
studi
particularli
signific
consid
challeng
dose
viru
use
pfu
far
greater
like
encount
upon
natur
exposur
human
influenza
viru
signific
reduct
viru
titer
observ
even
sirna
complex
administ
h
infect
lung
analyz
day
infect
result
impli
sirna
complex
appropri
synthet
vector
pei
may
potenti
util
prophylaxi
human
determin
effect
sirna
deliveri
treat
ongo
infect
mice
infect
pfu
treat
iv
paor
npsirna
complex
pei
h
infect
reduct
viru
titer
observ
case
npsirna
use
complex
pei
viru
titer
drop
undetect
level
repres
reduct
signific
ca
reduct
viru
titer
observ
even
sirna
administ
h
infect
lung
collect
h
later
independ
simultan
studi
tompkin
et
al
involv
sirna
differ
dose
strain
mice
viru
well
rout
administr
carrier
obtain
complementari
result
support
gener
approach
method
administr
sirna
employ
thompkin
et
al
rapid
iv
inject
larg
volum
sirna
solut
known
hydrodynam
high
pressur
transfect
method
rather
traumat
henc
unlik
use
human
compar
rout
administr
intranas
iv
inject
small
volum
therapeut
agent
reason
effect
prevent
treatment
influenza
viru
infect
human
sirna
requir
safe
effect
mean
deliveri
also
deliveri
vector
afford
cost
jetpei
vendor
ml
solut
thu
human
bodi
weight
ie
time
mous
amount
jetpei
requir
singl
inject
sirna
would
cost
ten
thousand
dollar
far
cheaper
linear
pei
similar
molecular
weight
avail
anoth
commerci
vendor
polysci
inc
warrington
pa
exhibit
markedli
lower
effici
specif
compar
jetpei
differ
appear
intrigu
therefor
decid
investig
mechan
involv
detail
nmr
analysi
indic
residu
acyl
group
commerci
linear
pei
found
remov
residu
nacyl
moieti
commerci
polym
simpl
acid
hydrolysi
elev
temperatur
enhanc
plasmid
dna
deliveri
effici
time
vitro
much
time
mice
concomit
enhanc
lung
specif
observ
indic
hydrolyt
puriti
pei
import
transfect
effici
specif
confirm
hypothesi
reduc
cost
still
three
addit
linear
pei
molecular
weight
synthes
ab
initio
acidcatalyz
hydrolysi
poli
polysci
sigmaaldrich
respect
yield
pure
polyc
isol
hydrochlorid
salt
exhibit
highest
transfect
effici
vitro
commerci
deacyl
respect
moreov
deliv
dna
mous
lung
effici
pure
lower
concentr
importantli
lung
specif
improv
stem
increas
number
pei
protonat
nitrogen
presum
result
tighter
condens
plasmid
dna
better
endosom
escap
peidna
complex
evid
dnabind
experi
acidtitr
experi
respect
although
differ
number
protonat
nitrogen
fulli
deacyl
commerci
counterpart
profound
effect
polyc
behavior
illustr
follow
calcul
given
molecular
weight
ch
ch
nhmonomer
unit
averag
number
monom
number
also
length
contigu
stretch
potenti
protonat
nitrogen
assum
random
distribut
npropionyl
moieti
commerci
contigu
stretch
protonat
nitrogen
differ
may
substanti
affect
stabil
polyplex
travers
variou
extracellular
intracellular
barrier
involv
system
gene
deliveri
system
deliveri
mice
complex
sirna
model
gene
firefli
luciferas
afford
respect
suppress
gene
express
lung
furthermor
polyplex
npsirna
result
drop
viru
titer
lung
influenzainfect
anim
respiratori
syncyti
viru
rsv
common
caus
seriou
respiratori
infect
mostli
bronchiol
pneumonia
infant
young
children
result
hospit
infant
less
week
old
children
underli
condit
prematur
birth
heart
diseas
lung
diseas
much
like
hospit
rsv
rsv
also
caus
coldlik
symptom
pneumonia
older
children
adult
http
wwwcdcgovncidodaipresearch
rsvhtml
immunocompromis
state
highrisk
popul
incomplet
immun
develop
even
natur
rsv
infect
short
incub
period
issu
complic
effect
vaccin
develop
infect
rsv
pneumoviru
envelop
nonseg
negativestrand
rna
viru
genom
approxim
nucleotid
transcrib
transcript
encod
distinct
protein
includ
two
nonstructur
protein
express
separ
mrna
encod
first
second
gene
respect
delet
either
drastic
attenu
rsv
infect
vivo
vitro
point
import
role
viral
replic
furthermor
repeat
rsv
infect
common
result
incomplet
immun
caus
natur
infect
basi
poorli
understood
rsv
infect
shown
associ
predominantli
helper
type
th
like
respons
infant
sinc
infant
experienc
rsv
bronchiol
like
develop
wheez
asthma
later
life
rsv
consid
predispos
factor
develop
allerg
diseas
asthma
recent
two
group
independ
employ
sirnabas
approach
inhibit
rsv
mice
outlin
zhang
et
al
use
shrnabas
approach
rsv
infect
bovin
human
rsv
seem
antagon
ifnmedi
antivir
respons
author
reason
block
ns
gene
express
might
attenu
rsv
replic
provid
effect
antivir
immun
enhanc
therapi
rsv
thu
sirna
oligonucleotid
sequenc
rsv
clone
vector
pretransfect
complex
liposom
reagent
lipofectamin
cell
substanti
reduc
express
protein
viral
protein
h
infect
recombin
rsv
express
gfp
rgrsv
level
express
ifninduc
gene
infect
cell
treat
consider
alter
shown
microarray
data
wherea
cell
show
consider
decreas
rgrsvinfect
cell
number
viru
titer
effect
vero
cell
ifndefici
observ
also
parallel
studi
vero
cell
cotransfect
pegfp
siegfp
show
substanti
knockdown
egfp
gene
express
result
show
definit
role
attenu
rsv
replic
implic
ifn
pathway
process
plasmid
administ
complex
refer
nanochitosan
polym
nanogen
nasal
drop
day
viral
inocul
rsv
infect
pulmonari
patholog
balbc
mice
substanti
attenu
concomitantli
knockeddown
express
rsv
gene
addit
viral
titer
supernat
homogen
lung
also
significantli
decreas
mice
compar
control
mice
treat
display
significantli
lower
airway
hyperreact
ahr
untreat
mice
well
consider
reduct
pulmonari
inflamm
evidenc
decreas
goblet
cell
hyperplasia
bronchi
number
infiltr
inflammatori
cell
interstiti
region
compar
control
knockdown
rsv
gene
significantli
increas
express
lung
compar
control
examin
level
bronchoalveolar
lavag
fluid
elisa
reveal
rise
concentr
mice
compar
control
anim
treatment
also
prophylact
effect
mice
treat
day
viral
inocul
analysi
viral
titer
day
infect
show
prophylact
effect
last
least
day
test
whether
prophylact
block
activ
induc
antirsv
immun
provid
protect
reinfect
mice
administ
inocul
rsv
pfumous
day
later
reinocul
rsv
pfumous
day
cellular
immun
induc
rsv
day
infect
examin
mice
intracellular
cytokin
stain
splenocyt
splenocyt
mice
treat
show
increas
product
cell
also
product
cell
compar
control
follow
secondari
infect
mice
treat
show
drop
viral
titer
compar
control
mice
thu
prophylaxi
enhanc
cellular
immun
attenu
secondari
rsv
infect
bikto
et
al
employ
sirna
p
protein
phosphoprotein
essenti
transcript
factor
l
protein
larg
protein
rsv
inhibit
viru
balbc
mice
administ
sirna
complex
transittko
proprietari
polycationliposom
formul
miru
corpor
madison
wi
reagent
intranas
h
later
challeng
anim
pfu
rsv
intranas
sirna
effect
vitro
also
found
highli
effect
vivo
dose
nmol
intranas
sirna
averag
doublestrand
sirna
per
mous
sirna
p
protein
mrna
refer
sirna
slash
pulmonari
rsv
titer
notabl
sirna
alon
ie
free
transfect
reagent
also
significantli
reduc
pulmonari
viral
titer
final
intranas
sirna
without
transittko
reagent
caus
obviou
discomfort
uninfect
mice
judg
normal
coat
activ
appetit
weight
gain
lack
respiratori
distress
suggest
favor
pharmacolog
drug
develop
separ
intranas
pretreat
nmol
antirsv
sirna
complex
transittko
abolish
rsv
infect
sirna
administ
without
transfect
reagent
also
show
substanti
reduct
infect
reagentfre
sirna
effect
sirna
complex
transittko
sirna
treatment
also
cur
effect
alreadi
infect
mice
import
goal
pediatr
medicin
rsvinfect
mice
maintain
bodi
weight
day
infect
follow
gradual
loss
continu
least
day
confirm
previou
observ
contrast
mice
treat
sirna
time
rsv
continu
gain
weight
without
interrupt
mice
receiv
sirna
day
also
difficult
distinguish
shaminfect
control
receiv
sirna
subsequ
day
show
gradual
less
less
protect
although
substanti
improv
weight
still
observ
rsvinfect
mice
viral
titer
rose
day
slowli
drop
undetect
level
day
sirna
treatment
concomitantli
rsv
infect
slash
titer
day
test
administr
sirna
later
infect
progress
less
effect
viral
titer
gener
lower
untreat
control
day
test
observ
suggest
rsv
p
sirna
cur
effect
administ
infect
treat
mice
alway
less
sick
recov
rapidli
untreat
cohort
two
studi
involv
two
differ
rnai
methodolog
synthet
sirna
plasmidencod
shrna
mrna
direct
two
differ
protein
p
protein
respect
rsv
interestingli
report
involv
intranas
deliveri
sirna
either
alon
complex
polyc
polycationlipid
coformul
taken
togeth
two
report
demonstr
sirna
deliveri
lung
viabl
therapeut
strategi
rsv
infect
worth
note
sinc
public
paper
human
monoclon
antibodi
rsv
palivizumab
http
wwwmedimmunecom
becom
avail
accord
medimmun
synagi
significantli
reduc
hospit
first
month
prematur
infant
born
less
week
infant
less
month
age
chronic
lung
diseas
requir
treatment
last
month
children
month
younger
hemodynam
signific
heart
diseas
new
antirsv
antibodi
numax
medimmun
inc
appear
even
effect
anim
undergo
clinic
trial
sinc
sar
sever
acut
respiratori
syndrom
newli
emerg
diseas
safe
effect
vaccin
yet
avail
although
candid
vaccin
advanc
monkey
model
clinic
test
individu
sar
usual
develop
high
fever
follow
sever
clinic
symptom
includ
ar
diffus
alveolar
damag
dad
autopsi
caus
sar
corona
viru
scv
identif
scv
caus
pathogen
sar
achiev
mainli
demonstr
exposur
cynomolgu
macaqu
scv
result
symptom
similar
individu
sar
sever
research
group
report
vitro
inhibit
scv
li
et
al
extend
studi
rhesu
macaqu
macaca
mulatta
model
sirna
show
promin
prophylact
therapeut
activ
cell
cultur
refer
select
sirna
duplex
target
entir
scv
genom
evalu
vivo
use
initi
report
gene
assay
mice
subsequ
clinic
accept
intranas
administr
recent
establish
rhesu
macaqu
sar
model
two
sirna
duplex
target
scv
genom
spike
proteincod
region
respect
target
sequenc
ident
strain
use
cellcultur
studi
strain
use
macaqu
model
anoth
publish
scv
strain
isol
differ
phase
scv
evolut
recent
defin
wide
geograph
distribut
around
world
moreov
two
potent
inhibitor
reduc
scv
replic
cell
among
set
activ
sirna
duplex
synergist
antiscv
activ
observ
combin
appli
cellcultur
studi
show
strongest
prophylact
therapeut
effect
li
et
al
first
test
equimolar
mixtur
refer
well
two
unrel
control
sirna
siconcd
mice
sirna
deliv
intratrach
aqueou
glucos
infasurf
forest
laboratori
inc
new
york
ny
infasurf
prescript
pharmaceut
instil
lung
newborn
infant
risk
respiratori
failur
steril
organ
solvent
extract
calf
lung
lavag
contain
surfact
protein
b
c
spb
c
proteinb
level
closest
natur
surfact
sirna
codeliv
pciscluc
plasmid
pciscluc
plasmid
contain
correspond
dna
sequenc
cytomegaloviru
promoterdriven
transcript
initi
site
luciferas
encod
sequenc
setup
allow
easi
monitor
deliveri
effici
luc
assay
interestingli
codeliveri
glucos
result
higher
level
report
gene
express
stronger
rnai
effect
deliv
infasurf
solut
henc
former
ie
nake
sirna
employ
glucos
experi
rhesu
macaqu
sirna
instil
intranas
observ
sarslik
symptom
measur
scv
rna
presenc
lung
histopatholog
immunohistochemistri
consist
show
sirnamedi
antisar
efficaci
either
prophylact
therapeut
regimen
sirna
use
provid
relief
scv
infectioninduc
fever
diminish
scv
viral
level
reduc
acut
diffus
alveoli
damag
mgkg
accumul
dosag
sirna
show
sign
sirnainduc
toxic
sever
proofofprincipl
experi
mice
monkey
potenti
treatment
lung
diseas
human
shown
encourag
result
intranas
intraven
rout
involv
nake
sirna
well
complex
polycation
liposom
vector
test
unlik
system
deliveri
nake
sirna
deliveri
intranas
produc
gene
silenc
compar
deliv
vector
signific
given
slow
progress
gene
therapi
clinic
due
lack
safe
effici
vector
alnylam
pharmaceut
massachusettsbas
biotechnolog
compani
http
wwwalnylamcom
recent
complet
two
phase
clinic
trial
sirna
evalu
safeti
toler
pharmacokinet
healthi
adult
volunt
trial
doubleblind
placebocontrol
random
total
human
subject
enrol
trial
expos
subject
receiv
singl
multipl
daili
dose
aln
salin
placebo
nasal
spray
aln
found
safe
administ
relev
dose
mild
advers
event
profil
compar
placebo
evid
laboratori
electrocardiograph
abnorm
subject
expos
drug
signific
system
exposur
aln
administ
intranas
nastech
seattlebas
biotechnolog
compani
http
wwwnastechcom
current
develop
sirna
influenza
therapeut
target
conserv
region
influenza
viral
genom
sirna
expect
effect
known
human
avian
influenza
strain
alnylam
also
develop
rnai
therapeut
pandem
flu
sirna
therapeut
san
franciscobas
compani
http
wwwsirnacom
explor
potenti
local
deliveri
sirna
lung
treatment
respiratori
diseas
includ
asthma
chronic
obstruct
pulmonari
diseas
copd
viral
infect
success
demonstr
extend
lung
exposur
suitabl
day
dose
limit
system
exposur
follow
lung
administr
formul
chemic
modifi
sirna
asthma
program
potent
efficaci
sirna
develop
target
inflammatori
cytokin
respons
drive
airway
inflamm
underli
airway
hyper
respons
patient
asthma
close
progress
made
area
sirnabas
strategi
treatment
respiratori
diseas
less
year
seem
promis
appear
sirna
therapeut
lung
diseas
fast
track
clinic
